Status:

COMPLETED

A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence

Lead Sponsor:

FemmePharma Global Healthcare, Inc.

Conditions:

Urinary Incontinence, Urge

Eligibility:

FEMALE

18-75 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.

Eligibility Criteria

Inclusion

  • Females 18 to 75 years of age
  • Has reported symptoms of urge urinary incontinence/overactive bladder

Exclusion

  • Is pregnant or lactating
  • Has had lower urinary tract surgery within 6 months prior to Screening
  • Has a history of urinary retention

Key Trial Info

Start Date :

July 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2008

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT00749632

Start Date

July 1 2007

End Date

October 1 2008

Last Update

October 15 2009

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

SNBL Clinical Pharmacology Center

Baltimore, Maryland, United States, 21201

2

Advanced Biomedical Research

Hackensack, New Jersey, United States, 07601